ZIOPHARM Oncology Inc(ZIOP): For the most recent quarter end, ZIOPHARM Oncology Inc reported Annual Earnings of $-0.11. Based on the filings, last years Annual Earnings was, $-0.41. For the most recent quarter end, ZIOP reported a surprise Earnings per Share of 0% . The consensus estimate for current quarter is $-0.11 and for the current fiscal year, the estimate is $-0.52. For the Next fiscal year, the estimate is $-0.96 based on the consensus.
ZIOPHARM Oncology Inc has received $-0.11 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.14 while the top line estimate is $-0.09 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -22.22%.
ZIOPHARM Oncology Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.11 EPS for the quarter. Analyst had a consensus estimate of $-0.11. The company had revenue of $1.60 million for the quarter, compared to analysts expectations of $1.45 million. The companys revenue was down -15.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.14 EPS.
Company has reported several Insider transactions to the SEC, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at 12.84 per share price.On Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at 10.12 per share price.On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at 9.67 per share price.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) witnessed a decline in the market cap on Wednesday as its shares dropped 1.17% or 0.08 points. After the session commenced at $6.74, the stock reached the higher end at $6.85 while it hit a low of $6.71. With the volume soaring to 697,571 shares, the last trade was called at $6.74. The company has a 52-week high of $9.74. The company has a market cap of $892 million and there are 132,376,670 shares in outstanding. The 52-week low of the share price is $4.45.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.